Abstract
Diabetic retinopathy (DR) and diabetic macular edema (DME) are frequent long term ocular complications in diabetic patients and may produce serious effects on visual acuity (VA), sometimes leading to blindness. The high and increasing prevalence of diabetes worldwide suggests that both complications will continue to be the main cause of vision loss and associated impairment for a long time [1]. The development and progression of DR is related to blood glucose concentration and is slowed by intensive glycemic control [2].
Current Diabetes Reviews
Title: Rubosixtaurin and other pkc Inhibitors in Diabetic Retinopathy and Macular Edema. Review
Volume: 5 Issue: 1
Author(s): M. Isabel Lopez Galvez
Affiliation:
Abstract: Diabetic retinopathy (DR) and diabetic macular edema (DME) are frequent long term ocular complications in diabetic patients and may produce serious effects on visual acuity (VA), sometimes leading to blindness. The high and increasing prevalence of diabetes worldwide suggests that both complications will continue to be the main cause of vision loss and associated impairment for a long time [1]. The development and progression of DR is related to blood glucose concentration and is slowed by intensive glycemic control [2].
Export Options
About this article
Cite this article as:
Lopez Galvez Isabel M., Rubosixtaurin and other pkc Inhibitors in Diabetic Retinopathy and Macular Edema. Review, Current Diabetes Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339909787314167
DOI https://dx.doi.org/10.2174/157339909787314167 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Current Alzheimer Research Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews Preface [HotTopic: Cytokine Therapies for Diabetic Microvascular Complications (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) The Effects of Angiotensin II Signaling Blockade on Platelet Activity in Subjects with Hypertension
Current Hypertension Reviews Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Analysis of Protein Glycation Products by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry
Current Medicinal Chemistry DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Preventive and Therapeutic Potentials of Anthocyanins in Diabetes and Associated Complications
Current Medicinal Chemistry Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Cellular and Molecular Pathways that Lead to Progression and Regression of Renal Fibrogenesis
Current Molecular Medicine Drosophila Renal Organ as a Model for Identification of Targets and Screening of Potential Therapeutic Agents for Diabetic Nephropathy
Current Drug Targets Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade
Current Drug Targets Multitarget Drugs of Plants Origin Acting on Alzheimer's Disease
Current Medicinal Chemistry Mechanisms of Renal Microvascular Dysfunction in Type 1 Diabetes: Potential Contribution to End Organ Damage
Current Vascular Pharmacology